Papillary thyroid carcinoma (PTC) is the most common cancer of the endocrine system and accounts for most thyroid cancer cases in the past decades. PTC is usually indolent and curable and has a 5-year survival rate >95%. However, in some cases, PTC will de-differentiate and become aggressive, resulting in a poor prognosis. Previous reports have revealed that genetic alterations, such as BRAF mutations, TERT mutations, can promote tumor proliferation and metastasis, which result in poor PTC prognosis; these actions are mediated through the Mitogen-Activated Protein Kinase (MAPK/ERK) and Phosphoinositide 3-kinase (PI3K) / Protein kinase B (AKT) pathways. However, the pathogenesis of PTC has not yet been fully elucidated.
To support clinical researches, CD Genomics utilizes targeted NGS sequencing technology to provide more efficient and accurate targeting of specific genes or mutations, and even to detect low frequency variations in thyroid carcinoma-associated genes. If necessary, you can choose genes that fit your requirements.
| AKT1 | BRAF | CDKN2A | CTNNB1 | EGFR | HRAS | hTERT | KRAS | NOTCH1 | NRAS |
| PIK3CA | PTEN | TP53 | TSHR |
 |
Sample Requirements
|
 |
Sequencing
|
 |
Bioinformatics Analysis We provide customized bioinformatics analysis including:
|
CD Genomics provides the accurate and cost-effective thyroid carcinoma panel sequencing and bioinformatics analysis. Our professional expert team executes quality management, following every procedure to ensure confident and unbiased results. The general workflow for thyroid carcinoma panel sequencing is outlined below.
For more information about the thyroid carcinoma panel or need other amplification requirements, please contact us.
References:
